Immuneering Corporation (IMRX)

NASDAQ: IMRX · Real-Time Price · USD

5.65

-0.02 (-0.35%)

At close: Dec 19, 2025, 4:00 PM EST

5.62

-0.03 (-0.53%)

After-hours: Dec 19, 2025, 5:27 PM EST

Immuneering Employees

Immuneering had 66 employees as of December 31, 2024. The number of employees decreased by 2 or -2.94% compared to the previous year.

Employees

66

Change (1Y)

-2

Growth (1Y)

-2.94%

Revenue / Employee

n/a

Profits / Employee

-$946,915

Market Cap

364.82M

Employees Chart

Employees History

Date	Employees	Change	Growth
Dec 31, 2024	66	-2	-2.94%
Dec 31, 2023	68	-5	-6.85%
Dec 31, 2022	73	9	14.06%
Dec 31, 2021	64	38	146.15%
Dec 31, 2020	26	-	-

Related Stocks

Company Name	Employees
UnitedHealth Group	400,000
Johnson & Johnson	138,100
Thermo Fisher Scientific	125,000
Abbott Laboratories	114,000
AstraZeneca	92,900
Novo Nordisk	77,349
Novartis AG	75,883
Merck & Co.	75,000

Employee Rankings

IMRX News

2 days ago - Immuneering Advances Towards Dosing First Patient in Phase 3 Atebimetinib Trial for First-Line Metastatic Pancreatic Cancer Patients, Securing Alignment with FDA and EMA - GlobeNewsWire
4 days ago - Immuneering to be Added to the Nasdaq Biotechnology Index (NBI) - GlobeNewsWire
25 days ago - Immuneering to Present at the Piper Sandler 37th Annual Healthcare Conference - GlobeNewsWire
5 weeks ago - Immuneering Corporation (IMRX) Q3 2025 Earnings Call Transcript - Seeking Alpha
5 weeks ago - Immuneering Reports Third Quarter 2025 Financial Results and Provides Business and Clinical Updates - GlobeNewsWire
6 weeks ago - Immuneering to Report Third Quarter 2025 Financial Results and Provide New Clinical Case Studies, on Wednesday, November 12, 2025 - GlobeNewsWire
2 months ago - Immuneering Corporation - Special Call - Seeking Alpha
3 months ago - Immuneering to Discuss Recently Announced Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on Monday, September 29, 2025 - GlobeNewsWire